Rhinomed Limited
RHNMF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 95.7% | 20.8% | -40.2% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 8.8% | -16.3% | 72.4% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 100% | -108.6% | -124.3% | -40.3% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0% | -153% | -137.6% | -35.9% |
| EPS Diluted | 0 | -0.022 | -0.016 | -0.008 |
| % Growth | 100% | -34.4% | -114.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |